Eldian Biomed is developing CloudLi, a novel disease-modifying therapy for osteoarthritis. CloudLi is an injectable microcushion formed by crosslinked liposomes with anti-inflammatory peptides that provide both mechanical cartilage protection and anti-inflammatory effects. This dual-action approach addresses the key drivers of OA progression cartilage wear and inflammation offering a safer, longer-lasting alternative to steroids and hyaluronic acid. Supported by early in vivo proof-of-concept and a strong academic network, Eldian is optimizing its lead candidate in large animal models to de-risk development and attract commercial partners. Its modular platform holds potential for broader applications in joint disease and combination therapies.